The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) 5 in most patients with myeloproliferative neoplasm (MPN) led to the clinical development of JAK2 kinase inhibitors 6, 7 . JAK2 inhibitor therapy improves MPN-associated splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN. We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2. Here we show that JAK2 inhibitor persistence is associated with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 in trans by other JAK kinases. Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is associated with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression. We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors. RNA interference and pharmacological studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression. Consequently, therapies that result in JAK2 degradation retain efficacy in persistent cells and may provide additional benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.
The identification of somatic activating mutations in JAK2 (refs [1] [2] [3] [4] and in the thrombopoietin receptor gene (MPL) 5 in most patients with myeloproliferative neoplasm (MPN) led to the clinical development of JAK2 kinase inhibitors 6, 7 . JAK2 inhibitor therapy improves MPN-associated splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN. We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2. Here we show that JAK2 inhibitor persistence is associated with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 in trans by other JAK kinases. Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is associated with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression. We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors. RNA interference and pharmacological studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression. Consequently, therapies that result in JAK2 degradation retain efficacy in persistent cells and may provide additional benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.
The development of targeted therapies has improved outcomes for patients with kinase-mutant malignancies [8] [9] [10] [11] ; however, acquired resistance due to mutations in the target kinase [12] [13] [14] or in other pathways that render cancer cells insensitive to kinase inhibitor therapy [15] [16] [17] [18] remain important clinical concerns. Although JAK inhibitors are now being used to treat patients with MPN, so far JAK inhibitor treatment has not been associated with significant decreases in disease burden in most patients with MPN 6, 7 . To understand mechanisms by which MPN cells survive despite chronic JAK kinase inhibition, we performed saturation mutagenesis 19 and next-generation sequencing in cells exposed to two structurally different JAK2 inhibitors, INCB18424 and JAK Inhibitor I. We identified second-site mutations in less than 30-50% of cells exposed to JAK2 inhibitors (Supplementary Table 1 ). Full-length resequencing of clones proliferating in the presence of INCB18424 or JAK Inhibitor I confirmed the absence of second-site JAK2 mutations in most surviving clones, and we did not identify second-site JAK2 mutations in granulocytes from five patients with MPN who had been treated with INCB18424. By contrast, control experiments with mutagenized BCR-Abl cells exposed to imatinib identified more than 20 known, clinically relevant, imatinib resistance alleles 19, 20 (data not shown).
These data and clinical experience suggest that the failure of JAK2 inhibitors to decrease disease burden is not due to acquired drug resistance but rather due to persistent growth and signalling in the setting of chronic JAK2 kinase inhibition. We therefore investigated the basis by which JAK2-dependent cells persist despite chronic JAK2 kinase inhibition. We cultured SET-2/UKE-1 (JAK2V617F-positive leukaemia) cells and Ba/F3 cells expressing JAK2V617F (EporVF) or MPLW515L (WL) cells with INCB18424 or JAK Inhibitor I for 4-6 weeks. In each case we found that JAK2/MPL-mutant cells could survive and proliferate at inhibitor concentrations sufficient to prevent the growth of parental cells (Fig. 1a, b and Supplementary Figs 1a and 2a). JAK2-inhibitor-persistent (JAK2 Per ) cells were resistant to INCB18424-induced apoptosis ( Supplementary Fig. 3 ). JAK2 resequencing confirmed the absence of second-site mutations in all JAK2 Per cell lines. JAK2 Per cells were also insensitive to structurally divergent JAK inhibitors, including TG101348, a JAK2-selective inhibitor in late-stage clinical trials ( Fig. 1c and Supplementary Figs 1b, c, 2b and 4). These data indicate that JAK2 Per cells are *These authors contributed equally to this work. 1 insensitive to different JAK inhibitors regardless of previous exposure to that inhibitor.
These data are consistent either with the selection of a subpopulation of pre-existing, persistent cells, as previously posited for epidermal growth factor receptor (EGFR) inhibitor-insensitive 'drug-tolerant persisters' 21 , or with the acquisition of persistence by naive, inhibitorsensitive cells. To distinguish between these possibilities, we derived single-cell clones of inhibitor-naive JAK2/MPL mutant cell lines. Each clonally derived naive cell line was sensitive to JAK inhibitors and retained the capacity to become persistent over time to different JAK inhibitors ( Supplementary Fig. 5 and data not shown). These data depict a general capacity for persistence in the absence of clonal selection.
Next, we assessed signalling downstream of JAK2 in JAK2 Per cells. We observed dose-dependent inhibition of downstream signalling in naive cells treated with INCB18424 or JAK Inhibitor I, but not in INCB18424 Per ( Fig. 2a and Supplementary Fig. 6a ) or JAK Inhibitor I Per cells ( Supplementary Fig. 6b ). Similarly, ex vivo treatment of granulocytes from patients chronically treated with INCB18424 demonstrated sustained downstream signalling at inhibitor concentrations that inhibited signalling in naive MPN patient samples ( Fig. 2b ). We then examined whether persistence was associated with constitutive JAK2 activation. We observed persistent phosphorylation of JAK2 in JAK2 Per cells ( Supplementary Figs 2c  and 6c ). Further, gene expression analysis showed that the expression of known JAK-STAT target genes was maintained in JAK Per cells, whereas these genes were suppressed with acute treatment of inhibitor-naive parental cells ( Supplementary Fig. 7) .
Given that JAK inhibitors should inhibit JAK2 autophosphorylation, we reasoned that other kinases might associate with and phosphorylate JAK2 in persistent cells. Although EpoR and MPL predominantly signal through JAK2 (ref. 22) , previous studies have shown that many cytokine receptors signal through JAK kinase heterodimers 23 . We therefore assessed the activation status of JAK1, JAK3 and TYK2 in naive and persistent SET-2 and WL cells. We observed increased phosphorylation of JAK1 in JAK2 Per cells in comparison with parental cells, whereas TYK2 was constitutively phosphorylated in both parental and JAK2 Per cells (Fig. 2c) . Accordingly, immunoprecipitation studies demonstrated that JAK1 and TYK2 associated with phosphoJAK2 in JAK2 Per SET-2, WL ( Fig. 2d ) and UKE-1 ( Supplementary Fig. 2d ) cells, but not in the respective parental cells. We saw a similar association between phosphoJAK2 and JAK1 or TYK2 in INCB18424-treated patient samples but not in inhibitornaive patient samples ( Fig. 2e and Supplementary Table 2 ).
Next, we examined whether the JAK Per cells were insensitive to JAK inhibitors. In vitro kinase assays revealed that the JAK Per heterodimer complex could phosphorylate myelin basic protein at concentrations of INCB18424 sufficient to inhibit JAK2 kinase activity in naive SET-2 cells ( Supplementary Fig. 8 ). These data suggest that the heterodimer complex in JAK Per cells retains kinase activity that is relatively insensitive to JAK inhibitors. To determine whether JAK1-mediated phosphorylation of JAK2 was insensitive to INCB18424, we coexpressed a constitutively active mutant form of JAK1 (JAK1V658F) 24 with kinase-dead JAK2 (JAK2K882E) in JAK2-deficient c2A cells. We observed persistent JAK2 phosphorylation in JAK1V658F/JAK2K882E c2A cells exposed to INCB18424 at concentrations sufficient to inhibit JAK2 autophosphorylation ( Supplementary Fig. 9 ).
We then investigated whether persistence of JAK2 inhibitor was reversible. We removed INCB18424 or JAK Inhibitor I for 2-4 weeks; this led to JAK inhibitor resensitization ( Fig. 3a and Supplementary  Fig. 10a, b ). Resensitized (JAK2 Resens ) cells were sensitive to all three JAK inhibitors, suggesting that patients with MPN may respond to retreatment or to a different JAK2 inhibitor after a brief withdrawal of treatment. JAK1 or TYK2 association with phosphoJAK2 was lost in JAK2 Resens cells ( Fig. 3b and Supplementary Fig. 10c ), and activated JAK2 levels were lower in JAK2 Resens cells ( Supplementary Fig. 10d ).
Previous work attributed persistence in EGFR inhibitor-insensitive 'drug-tolerant persisters' 21 to the engagement of alternative survival pathways. By contrast, JAK Per cells were characterized by JAK-STAT pathway reactivation (Fig. 2) . We therefore speculated that changes in 
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the epigenetic regulation of JAK2 might contribute to JAK inhibitor persistence. JAK2 messenger RNA ( Supplementary Fig. 11 ) and JAK2 protein ( Fig. 3c and Supplementary Figs 2e and 10e ) levels were higher in JAK2 Per cells than in parental cells, and were lower in JAK2 Resens cells. Chromatin immunoprecipitation sequencing (ChIP-Seq) analysis of naive JAK2-mutant SET-2 cells (M.A., O.A.W., B.E.B. and R.L.L., unpublished observations) revealed that the JAK2 locus is characterized by trimethylation of histone H3 on Lys 4 (H3K4me3), a modification associated with active promoters, and by H3K9 trimethylation, a mark more typically associated with inactive heterochromatin ( Supplementary Fig. 12a and Supplementary Table 3 ). Analysis of the JAK2 locus by ChIP coupled to quantitative polymerase chain reaction (ChIP-qPCR) showed a significant increase in H3K4me3 and a decrease in H3K9me3 in JAK2 Per cells in comparison with parental cells (Fig. 3d) , which is consistent with a change to a more active chromatin state at the JAK2 locus. However, global H3K4me3 levels in naive and persistent cells remained unchanged, which is consistent with specific effects on H3K4me3 at the JAK2 locus in persistent cells ( Supplementary Fig. 12b ). Given that JAK2 protein levels, and particularly phosphoJAK2 levels, increased with persistence, we examined whether JAK2 inhibitor persistence was also associated with post-transcriptional stabilization of total and activated JAK2. We have previously shown that JAK2 levels decline rapidly on treatment with cycloheximide in JAK2-mutant cells 25 . We noted a time-dependent decrease in phosphoJAK2 and total JAK2 levels in naive and resensitized WL/SET-2 cells; however, exposure to cycloheximide did not result in a significant decline in JAK2, or more notably in phosphoJAK2, in INCB18424 Per cells ( Fig. 3e and Supplementary Fig. 13 ). These data suggest that chronic treatment with inhibitor results in the stabilization of activated JAK2, which, combined with increased JAK2 mRNA expression, facilitates the formation of heterodimers.
We then assessed whether this phenomenon was observed in vivo. We treated mice engrafted with MPLW515L-mutant murine bone marrow 26 with vehicle or with INCB18424. Treatment with INCB18424 was associated with decreased splenomegaly; however, the proportion of malignant cells was not decreased on treatment with JAK inhibitor, in concordance with our previous results ( Supplementary Fig. 14a ) 26 . Treatment with INCB18424 was associated with an increase in JAK2 mRNA and JAK2 protein expression ( Supplementary Fig. 14b ), similar to that observed in JAK2 Per cells. We also observed an increase in JAK2 granulocyte mRNA levels in INCB18424-treated patients without clinical or molecular responses, in contrast with patients with clinical or molecular responses to INCB18424 (P 5 0.05) ( Fig. 3f and Supplementary Table 2 ). Finally, we noted increased JAK2 phosphorylation and increased association between JAK1 and JAK2 in haematopoietic cells from MPLW515L-mutant mice treated with INCB18424. (Supplementary Fig. 14c, d) , which is consonant with the expression data.
We examined whether JAK2 Per cells remain JAK2 dependent. JAK2 silencing inhibited proliferation (Fig. 4a) , JAK2 activation and 
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downstream signalling (Fig. 4b ) in naive and JAK2 Per SET-2 cells, which is consistent with a requirement for JAK2 expression in JAK2 Per cells. These data are consistent with previous studies in prolactin receptor cellular systems demonstrating that catalytically inactive JAK2 can serve as a scaffold for transactivation and downstream signalling 27 . However, this had not previously been implicated in JAK-dependent malignancies or in the response to JAK kinase inhibitors. Knockdown of JAK1 and TYK2 increased the sensitivity of SET-2 INCB18424 Per and SET-2 JAK Inhibitor I Per cells to INCB18424 and JAK Inhibitor I, respectively ( Fig. 4c and Supplementary Fig. 15a-c) , whereas the parental cells remained unaffected by JAK1 and TYK2 knockdown ( Supplementary Fig. 15d ). Further, JAK1 and TYK2 knockdown led to decreased downstream signalling and decreased JAK2 phosphorylation in the persistent cells (Supplementary Fig. 15e, f) . We next assessed whether new therapeutic approaches might reverse JAK inhibitor persistence. We previously reported that Hsp90 inhibitors increase JAK2 degradation in vitro and in vivo 25 . JAK2 Per and parental cells were equally sensitive to Hsp90 inhibition by PU-H71 ( Fig. 4d and Supplementary Fig. 16a ), and PU-H71 treatment led to JAK2 degradation and inhibited signalling in JAK2 Per cells (Fig. 4e ). The currently available type I JAK inhibitors are conformation dependent and can only engage activated JAK2 (ref. 28) . We therefore tested the effects of BBT-594, a type II inhibitor that retains the ability to bind inactive JAK2 (ref. 28) , in JAK2 Per cells. BBT-594 inhibited the proliferation, JAK activation, and signalling of naive and JAK Per cells to a similar extent ( Fig. 4f and Supplementary Fig. 16b, c) .
Taken together, our results suggest that kinase inhibitor persistence can occur through reversible changes in JAK2 expression and transphosphorylation ( Supplementary Fig. 17 ). We show that persistent JAK2 activation in the setting of exposure to JAK inhibitor allows cells to survive without decreasing dependence on JAK2 expression. Consequently, treatments that lead to JAK2 degradation (Hsp90 inhibitors or histone deacetylase inhibitors) 29, 30 or that retain the ability to inhibit JAK2 in persistent cells have the potential to improve therapeutic efficacy in patients with MPN.
METHODS SUMMARY
Generation of JAK2-inhibitor-persistent cells. Cells were cultured continuously in increasing concentrations of INCB18424 or JAK Inhibitor I for 4-6 weeks. Cells were considered resistant when the half-maximal inhibitory concentrations (IC 50 values) of the persistent derivatives were at least double the IC 50 of parental cells (verified by in vitro inhibitor assays). Persistent cells were cultured continuously in the presence of the JAK2 inhibitor. For resensitization experiments, inhibitor was withdrawn from the medium and cells were cultured in the absence of the drug for 2-4 weeks. Knockdown of JAK2 and TYK2 in human cell lines. Short hairpin RNA (shRNA) for JAK2 was purchased from the High Throughput Drug Screening Facility at Memorial Sloan-Kettering Cancer Center, or was a gift from L. Staudt. 
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shRNA against TYK2 was a gift from T. Look. Whenever required, shRNA oligonucleotides were cloned into pLKO lentiviral systems. Cell lines were transfected with lentivirus, and selected with puromycin. Short interfering RNA (siRNA) targeting either JAK1 or TYK2 was purchased from Invitrogen and used in accordance with the manufacturer's instructions.
Murine model and analysis of mice. The MPLW515L murine BMT assay was performed as described previously 5 . Sick mice were randomized to receive INCB18424 twice daily at 60 and 90 mg kg 21 or vehicle (0.5% methylcellulose) by oral gavage. Mice were treated for 28 days or until any one of several criteria for killing were met, including moribundity, more than 10% body weight loss, and palpable splenomegaly extending across the midline. Animal care was in strict compliance with Memorial Sloan-Kettering Cancer Center guidelines. Bone marrow and spleen cells were strained and viably frozen in 90% FCS and 10% DMSO.
Full Methods and any associated references are available in the online version of the paper.
